NCT05724212 (IGRA/MAT-1) is a clinical trial of Interferon gamma release assay (IGRA) in Tuberculosis, sponsored by Paola Mantegani.

Who is sponsoring NCT05724212?

NCT05724212 is sponsored by Paola Mantegani.

What drugs are being tested in NCT05724212?

Interventions in NCT05724212: Interferon gamma release assay (IGRA).

What condition does NCT05724212 study?

NCT05724212 studies Tuberculosis.

Is NCT05724212 still recruiting?

NCT05724212 is currently active, enrolled. Last updated 26 September 2024.

Last reviewed 2024-09-26 · How we verify

NCT05724212: IGRA/MAT-1

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of a CD4/CD8+ Interferon Gamma Release Assay for Monitoring Anti-Tuberculosis Treatment

Active, enrolled Last updated 26 September 2024

What this trial tests

trial testing Interferon gamma release assay (IGRA) in Tuberculosis in 220 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

27 January 2017

Primary endpoint
13 May 2021

1 February 2025

Quick facts

Lead sponsor	Paola Mantegani
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	220
Start date	27 January 2017
Primary completion	13 May 2021
Estimated completion	1 February 2025
Sites	1 location across Italy

Drugs / interventions tested

Interferon gamma release assay (IGRA)

Conditions studied

Tuberculosis — all drugs for Tuberculosis →

Sponsor

Paola Mantegani

Who can join

18 and older, any sex, with Tuberculosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluate the possibility of using an IGRA (Interferon-γ Release Assay) test for monitoring the response to anti-tuberculosis therapy by studying the correlation between the variation in the Interferon-gamma (IFN-γ) response to the QFT-Plus test in the two tubes containing antigens and the gold standard for monitoring TB therapy (culture conversion) in patients with slide positive/culture positive and slide negative/culture positive PTB. Evaluate the level of agreement between the results of the new QFT Access test and the results of the QFT plus and culture in patients diagnosed with active tuberculosis. To evaluate the level of agreement between QFT Access test results and QFT Plus results in healthy controls and contacts.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Tuberculosis

Currently open trials in the same condition.

NCT05917210 — Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda · NA · recruiting
NCT07170735 — Quantitative Measurement of Plasma and Urine MTB Cell-free DNA Level · recruiting
NCT07484490 — Effects of the Active Cycle of Breathing Technique With and Without Balloon Blowing Therapy in Tuberculosis · NA · recruiting
NCT06318416 — Precision Rifampin Trial for Personalized Dosing · Phase 1 · recruiting
NCT07170800 — A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05724212 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Paola Mantegani
Last refreshed: 26 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05724212.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing